Abstract:NOD-like receptor (NLR), family pyrin domain containing 3 (NLRP3) assembles a protein complex known as the NLRP3 inflammasome upon sensing certain pathogen products or sterile danger signals. Gain-of-function mutations such as the D301N substitution in NLRP3, which cause its constitutive activation (NLRP3CA) also results in inflammasome assembly. This inflammasome processes pro–interleukin-1 β (pro–IL-1β) and pro–IL-18 into bioactive IL-1β and IL-18, respectively, and cleaves gasdermin D (GSDMD). GSDMD amino-terminal fragments form plasma membrane pores that facilitate the secretion of IL-1β and IL-18 and lead to the inflammatory cell death pyroptosis. Accordingly, GSDMD inactivation results in negligible spontaneous inflammation in various experimental models such as in Nlrp3CA/+ mice lacking GSDMD (Nlrp3CA/+;Gsdmd−/− mice). Here, we found that Nlrp3CA/+;Gsdmd−/− mice, when challenged with LPS or TNF-α, still secreted IL-1β and IL-18, indicating inflammasome activation independent of GSDMD. Accordingly, Gsdmd−/− macrophages failed to secrete IL-1β and undergo pyroptosis when briefly exposed to NLRP3 inflammasome activators but released these cytokines when persistently activated. Sustained NLRP3 inflammasome induced caspase-8/-3 and GSDME cleavage and IL-1β maturation in vitro in Gsdmd−/− macrophages. Thus, a salvage inflammatory pathway involving caspase-8/-3–GSDME was activated after NLRP3 activation when the canonical NLRP3-GSDMD signaling was blocked. Consistent with genetic data, the active metabolite of FDA-approved disulfiram CuET, which inhibited GSDMD and GSDME cleavage in macrophages, reduced the severe inflammation and tissue damage that occurred in the Nlrp3CA/+ mice. Thus, NLRP3 inflammasome activation overwhelms the protection afforded by GSDMD deficiency, rewiring signaling cascades through mechanisms that include GSDME to propagate inflammation.

Epithelial-derived gasdermin D mediates nonlytic IL-1β release during experimental colitis

Epithelial Gasdermin D shapes the host-microbial interface by driving mucus layer formation

Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling

P059 GSDMB triggers intestinal inflammation via regulating BHLHA15-mediated hyperactive unfolded protein response

Gasdermin D Licenses MHCII Induction to Maintain Food Tolerance in Small Intestine.

Gasdermin D is an Executor of Pyroptosis and Required for Interleukin-1Β Secretion

GSDMD pore formation regulates caspase-4 cleavage to limit IL-18 production in the intestinal epithelium

Murine Eosinophils Release IL-1β via a Non-Lytic Mechanism Dependent on Gasdermin D (GSDMD) Expression but Independent of GSDMD Proteolytic Processing

Intestinal epithelial Gasdermin C is induced by IL-4R/STAT6 signaling but is dispensable for gut immune homeostasis

Gasdermin D promotes development of intestinal tumors through regulating IL-1β release and gut microbiota composition

Intestinal Gasdermins for regulation of inflammation and tumorigenesis

N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis

Gasdermin D pore structure reveals preferential release of mature interleukin-1

GSDMD protects intestinal epithelial cells against bacterial infections through its N-terminal activity impacting intestinal immune homeostasis

The Ras GTPase-activating-like protein IQGAP1 bridges Gasdermin D to the ESCRT system to promote IL-1β release via exosomes

Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death

Compound Loss of GSDMD and GSDME Function is Necessary to Achieve Maximal Therapeutic Effect in Colitis

To die or not to die: Gasdermins in intestinal health and disease

Gasdermin D is the only Gasdermin that provides protection against acute Salmonella gut infection in mice

NLRP3 Inflammasome Activation Triggers Gasdermin D–independent Inflammation

Intestinal epithelial expression of neutral ceramidase determines severity of chemical colitis in mice